
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: 1 The First Department of Oral and Maxillofacial Surgery, Stomatology School, Peking University, Beijing, China; 2 First Department of Oral and Maxillofacial Surgery, 3 Department of Pathology, Tokyo Dental College, Chiba; and 4 Second Department of Oral and Maxillofacial Surgery, Tokushima University, Tokushima, Japan
Requests for reprints: Takeshi Nomura, The First Department of Oral and Maxillofacial Surgery, Tokyo Dental College, 1-2-2 Masago, Mihama-Ku, Chiba City 261-8502, Japan. Phone: 81-43-270-3973; Fax: 81-43-270-3975; E-mail: tanomura{at}tdc.ac.jp.
Purpose: This study examined the mechanisms of osteoclast-mediated bone invasion in a model of oral squamous cell carcinoma (OSCC). C3H/HeN mice were inoculated with SCC VII cells into the masseter region to establish an animal model of mandibular invasion by OSCC.
Experimental Design: The mice were divided into three groups: a control group, given daily s.c. injections of saline; group 1, given 2 µg per mouse per day of the bisphosphonate YM529; and group 2, given 10 µg per mouse per day of YM529. After 3 weeks of treatment, the lesions were studied by micro-computed tomography. After tartrate-resistant acid phosphatase (TRAP) staining, the osteoclasts were easily identified, and the percentages of the area occupied by osteoclasts were calculated by computer for each sample. The tumors were analyzed by RT-PCR to determine the mRNA expression of interleukin-6 (IL-6), parathyroid hormonerelated protein (PTHrP), tumor necrosis factor-
(TNF-
), receptor activator of nuclear factor-
B (RANK), RANK ligand (RANKL), and osteoprotegerin.
Results: SCC VII cells rapidly multiplied in the masseter muscle of the mice. Bone invasion was evident only in the control group on micro-computed tomography. On TRAP-stained slices, the percentages of osteoclasts in groups 1 and 2 were significantly lower than that in the control group. The mRNA expressions of IL-6, PTHrP, THF-
, and RANK decreased as the concentration of YM529 increased.
Conclusions: We conclude that various cancer-derived cytokines play important roles in the invasion of bone by OSCC. YM529, a third-generation bisphosphonate, can suppress osteoclast-mediated bone invasion by OSCC. The mechanism of this effect might involve inhibition of cytokines such as IL-6, PTHrP, TNF-
, and RANK by YM529.
Key Words: oral cancer bone invasion bisphosphonate
This article has been cited by other articles:
![]() |
K. Inoue, T. Karashima, S. Fukata, A. Nomura, C. Kawada, A. Kurabayashi, M. Furihata, Y. Ohtsuki, and T. Shuin Effect of Combination Therapy with a Novel Bisphosphonate, Minodronate (YM529), and Docetaxel on a Model of Bone Metastasis by Human Transitional Cell Carcinoma Clin. Cancer Res., September 15, 2005; 11(18): 6669 - 6677. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |